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Gregory L. Moneta, MD, Section EditorA New Intercostal Artery Management Strategy for Thoracoabdominal
Aortic Aneurysm Repair
Mell MW, Wynn MM, Reeder SB, et al. J Surg Res 2009;54:99-104.
Conclusion: Identification of the anterior spinal artery, artery of Ad-
amkiewicz with magnetic resonance angiography (MRA), and subsequent
selective reimplantation of intercostal arteries during open thoracoabdomi-
nal aneurysm (TAA) repair may serve as an effective additional adjunct in
reducing immediate or delayed paraplegia after repair of TAAs.
Summary: Spinal cord ischemia (SCI) before the use of perioperative
protective measures occurred in 16% to 31% of patients undergoing TAA
repair. Advances in surgical technique, postoperative care, and anesthetic
management have been introduced to address the rate of SCI after TAA
repair. Intraoperative techniques have contributed to a reduction in the
occurrence of SCI with TAA repair. Some have used spinal angiography to
identify critical intercostal arteries; however, the technique has proved
difficult to use and is associated with some risk. Current advances in
computed tomography angiography (CTA) and MRA have made it possible
to noninvasively identify important intersegmental arteries in patients un-
dergoing TAA repair.
In this article the authors introduce a new adjunct for TAA repair that
involves the perioperative identification and selective implantation of critical
intercostal arteries based on preoperative MRA imaging. Included in this
study were patients undergoing TAA repair fromAugust 2005 to September
2007 at the University of Wisconsin. Spinal artery MRA was used to identify
the anterior spinal artery and its major intercostal source preoperatively.
Patients received intraoperative spinal cord protection using standard ad-
juncts. Intercostal arteries felt to be important were preserved or reim-
planted as a button after removal of aortic clamps. Perioperative and demo-
graphic data were retrospectively collected.
MRA of the spinal artery was performed in 27 patients with identifica-
tion of the anterior spinal artery in 85% of the studies. Open repair was
performed in 74% and endovascular repair in 26%. The major intercostal
source artery for the anterior spinal artery was preserved or reimplanted in 13
patients (65%) who underwent open repair. In seven patients (35%), there
was no attempt to preserve or reimplant any intercostal arteries because the
major source artery for the anterior spinal artery was not identified, was
diminutive (1.5 mm in diameter), not accessible, or was associated with
significant calcification. In the patients undergoing reimplantation, a mean
of 1.67 intercostal arteries were reimplanted (range, 1-3). Of the patients
undergoing endovascular repair, the major source intercostal artery for the
anterior spinal artery was covered in all cases. No immediate or delayed
paraplegia developed in any patient in either group.
Comment: The new adjunct here is essentially selective reimplantation of
intercostal arteries based on preoperative MRA imaging. It is impossible to
know whether this strategy will provide any additional benefit in reducing SCI.
In many patients in the open cohort, “important” intercostal arteries were not
reimplanted for technical reasons, and all of the patients who underwent
endovascular repair and in whom “important” intercostal arteries were identi-
fied preoperatively, those arteries were covered during the course of the endo-
vascular repair. No cases of paraplegia were documented in the reimplanted or
non-reimplanted patients treated with open repair, or in any of those treated
with endovascular repair. The potential utility of this approach is that if you are
a selective “reimplanter” of intercostal arteries during TAA repair it is possible,
perhaps, with preoperative MRA of the spinal cord circulation, to identify
precisely which intercostal arteries to reimplant. Whether this strategy will
ultimately result in decreased rates of paraplegia will require a relatively large,
multicenter randomized trial and is very unlikely ever to be performed.
AMS INSIGHT—Absorbable Metal Stent Implantation for Treatment
of Below-the-Knee Critical Limb Ischemia: 6-Month Analysis
Bosiers M, and the AMS INSIGHT Investigators. Cardiovasc Intervent
Radiol 2009;2:424-35.
Conclusion: Implantation of absorbable metal stents (AMSs) in below
knee popliteal arteries is safe but does not result in increased efficacy over
standard percutaneous angioplasty of infrapopliteal vessels.
Summary: Given the poor patency of infrapopliteal percutaneous
revascularizations, a number of strategies are being investigated in patients
with critical limb ischemia who have infrapopliteal occlusive disease. The
permanent presence of an artificial implant may contribute to restenosis of a
stented vessel. Stenting technology has led to the development of temporary
implants composed of biocompatible materials that can support the vessel
during the period of high risk for recoil but then completely degrade over
the long term. Bioabsorbable stents serve as a means to mechanically preventvessel recoil while avoiding the theoretic disadvantage of a long-term metal-
lic implant.
This study investigated the safety and efficacy of AMSs in infrapopliteal
arteries. Clinical follow-up was at 1 and 6 months, and efficacy was deter-
mined at 6 months by angiogram. There were 117 patients with 149 lesions
and critical limb ischemia (Rutherford categories 4 and 5) who were ran-
domized to implantation of an AMS (60 patients, 74 lesions) or stand-alone
percutaneous transluminal angioplasty (PTA; 57 patients, 75 lesions). Seven
PTA group patients crossed over to the stenting group. Lesions stented had
to have a50% diameter reduction with a vessel diameter of between 3 and
3.5 mm and a lesion length of 15 mm. The primary safety end point was
absence of major amputation or death30 days after the index intervention.
Primary efficacy end point was 6-month angiographic patency.
The 30-day complication rate for patients randomized to PTA alone
was 5.3% (3 of 57) and that for AMS implantation was 5% (3 of 60). An
intention to treat analysis showed angiographic patency for lesions treated
with AMS (31.8%) was lower than that for patients treated with PTA alone
(58.0%; P  .013).
Comment: The study confirms low short-term patency of infrapopli-
teal percutaneous interventions. It is disappointing that the bioabsorbable
stents did not improve patency of infrapopliteal interventions, and in fact,
appeared to be associated with worse results. The current results do not
support the positive clinical outcome of the initial AMS findings in a small
cohort of patients (J Endovasc Ther 2005;12:1-5). The technology appears
safe, but the stent will need to be improved and re-evaluated before
commercial use can be considered an option. Once again, the complex
biology of atherosclerosis and intimal hyperplasia appears to have beaten
some clever engineers.
Aortic Arch Plaques and Risk of Recurrent Stroke and Death
Di Tullio MR, Russo C, Jin Z, and the Patent Foramen Ovale in Crypto-
genic Stroke Study Investigators. Circulation 2009;19:2376-82.
Conclusion: Large aortic plaques are associated with an increased risk
of recurrent stroke and death at 2 years, even when patients are treated with
aspirin or warfarin therapy.
Summary: Large aortic plaques (4 mm), as determined by transesoph-
ageal echocardiography (TEE), confer an increase risk of stroke (J Am Coll
Cardiol 1994;23:1085-90). Ulceration and superimposed thrombi appear
to increase risk as well (Am Heart J 2000;139:329-36). It is assumed,
without much evidence, that anticoagulation or antiplatelet agents, or both,
prevent stroke in patients with large aortic plaques. In this study the authors
sought to define event rates in patients with stroke who had large aortic
plaques. Patients were randomly assigned in a double-blind fashion to
warfarin or aspirin treatment. The primary end point was recurrent ischemic
stroke or death resulting from any cause. Recurrent ischemic stroke was a
new lesion on magnetic resonance imaging or computed tomography scan-
ning. If new lesions were absent, a clinical syndrome consistent with stroke
lasting 24 hours was considered an end point.
There were 516 patients with ischemic stroke who were double-blindly
randomized. Large plaques (4 mm) were present in 19.6% of patients, and
large complex plaques, defined as those with mobile components or ulcer-
ations, were seen in 8.5%. During the 2-year follow-up period, large plaques
were associated with an increase risk of events (adjusted hazard ratio [HR],
2.12; 95% confidence interval [CI], 1.04-4.32). The HR was also increased
in those with complex plaque morphology (HR, 2.55; 95% CI, 1.10-5.89).
In patients with cryptogenic stroke, the HR was higher for both large
plaques (HR, 6.42; 95% CI, 1.62-25.46) and large complex plaques (HR,
9.50; 95% CI, 1.92-47.10). There were no differences in event rates in the
warfarin and aspirin groups compared with the overall study population
(16.4% vs 15.8%; P  0.43).
Comment: In this study large aortic plaques were associated with a
doubling of the risk of recurrent stroke and death despite medical therapy.
There was no difference between aspirin and warfarin therapy, and both
therapies were relatively ineffective. The HRs observed in this report ap-
peared only slightly lower than those previously reported from studies where
treatment was not randomized or even not prescribed (J Am Coll Cardiol
1994;23:1085-90). The study suggests that neither warfarin nor aspirin
significantly affect the risk of stroke associated with large aortic plaques.
Aspirin vs Anticoagulation in Carotid Artery Dissection: A Study of
298 Patients
Georgiadis D, Arnold M, von Buedingen HC, et al. Neurology 2009;72:
1810-5.
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spontaneous dissection of the cervical carotid artery is low and likely indepen-
dent of the type of antithrombotic treatment (aspirin or anticoagulants) used.
Summary: Antithrombotic treatment in patients with spontaneous
internal carotid artery dissection (sICAD) is largely empiric. Some form of
anticoagulation is standard treatment, but whether to use aspirin or vitamin
K antagonist is unclear. The authors evaluated the incidence and predictors
of ischemic events and adverse events associated with antithrombotic ther-
apy in patients with a first sICAD. Patients were stratified to whether they
were treated with aspirin alone or anticoagulants alone for at least 3 months
after their initial diagnosis. Data were collected prospectively and analyzed
retrospectively.
Of 298 consecutive patients with sICAD (56% men; mean age, 46  10
years), 202 were treated with anticoagulants alone and 96 with aspirin alone.
The admission diagnosis was ischemic stroke in 165, transient ischemic attack
(TIA) in 37, and retinal ischemia in 8.Eight patientswere asymptomatic, and80
had local symptoms and signs, such as headache, neck pain, Horner syndrome,
or cranial nerve palsy. After 3 months, clinical follow-up was obtained by
neurologic examination in 97% of patients. The remainder had a structured
telephone interview. Outcome measures were the development of a new cere-
bral ischemic event (ischemic stroke, TIA, or retinal ischemia, symptomatic
intracranial hemorrhage) and major extracranial bleeding.
Follow-up ischemic events were rare. Ischemic stroke occurred in 0.3%,
TIA in 3.4%, and retinal ischemia in 1%. The frequency of events did not
differ significantly between patients treated with anticoagulants (5.9%, P 
.1) and those treated with aspirin (2.1%, P  .2), with an odds ratio of 3.0
(95% confidence interval, 0.7-13.5). There was also no significant difference
in the development of hemorrhagic adverse events, with a 2% incidence in
patients treated with anticoagulants and 1% in those treated with aspirin.
New ischemic events appeared to be more frequent in patients who had
sustained initial ischemic events at the time of diagnosis of their sICAD
(6.2%) then in patients who had local symptoms or asymptomatic patients
(1.1%), although this did not quite reach statistical significance (P  .06).
Comment: There are several interesting points here. The first is the
overall low frequency of new ischemic events in patients who have sICAD
irrespective of the type of antithrombotic medication used for treatment.
The second is that the frequency of new ischemic events appears to be lower
in patients with sICAD who present with local symptoms or who were
asymptomatic at presentation. Finally, the results here suggest there is no
significant difference using aspirin or warfarin to treat sICAD. Two other
recent meta-analyses also confirm this observation (Cochrane Database
Systematic Review 2003;CD000255 and Stoke 2004;35:613-4). Spontane-
ous carotid artery dissection is adequately, and perhaps best, treated with
antiplatelet therapy.
Endoscopic versus Open Vein-Graft Harvesting in Coronary-Artery
Bypass Surgery
Lopes RD, Hafley GE, Allen KB, et al. N Engl J Med 2009;361:235-44.
Conclusion: Patients undergoing harvest of the saphenous vein with
endoscopic techniques for coronary artery bypass grafting (CABG) have
higher rates of late graft failure and death compared with patients undergo-
ing open harvest of the saphenous vein.
Summary: In recent years, harvest of saphenous veins using endo-
scopic techniques has become widely prevalent in CABG surgery. Endo-
scopic techniques are also frequently used when the saphenous vein is
harvested for infrainguinal bypasses. Endoscopic vein harvest avoids the long
incisions associated with open harvesting and, at least in CABG, appears to
decrease rates of wound infection, lessen postoperative pain, and perhaps
shorten the length of hospital stay. However, the endoscopic harvesting
technique is associated with significantmanipulation of the vein as well as the
use of thermal energy close to the vein lumen.
The authors sought to determine whether endoscopic vein harvesting
had any significant effects on survival and graft patency after CABG. The
data were derived from the Project of Ex-vivo Vein Graft Engineering via
Transfection (PREVENT) IV trial, a phase 3, multicenter, randomized,
double-blind, placebo-controlled trial of ex vivo treatment of vein grafts
with an E2F transcription factor decoy in patients undergoing CABG. More
than 3000 patients were enrolled at 107 sites in 2002 and 2003. The first
2400 patients were in an angiographic cohort and were asked to return for
angiographic assessment of their coronary bypass grafts 12 to 18 months
after surgery. Although PREVENT IV failed to confirm efficacy of E2F
transcription factor in reducing vein graft failure, it did provide a large
database for subsequent analysis. The authors used this database to assess the
effects of endoscopic vein graft harvesting on vein graft failure at 12 to 18
months and on clinical outcomes at 3 years after CABG.
Endoscopic harvesting for CABG was used in 1753 patients compared
with harvesting by direct vision in 1247 patients. The surgeon determined
the method of graft harvesting, and vein graft failure was defined as a75%
diameter reduction of the graft on angiography 12 to 18 months after
surgery. Angiograms were obtained in 1817 patients and 4290 grafts.
Clinical outcomes included repeat revascularization, myocardial infarction,
and death. Rates of vein graft failure were determined in open vs endovas-cularly harvested veins, adjusting for baseline covariance. Long-term clinical
outcomes were assessed with Cox proportional hazard modeling.
Baseline characteristics were similar between patients undergoing open
vs endoscopic vein harvesting. Patients who underwent endoscopic harvest-
ing had higher rates of vein graft failure 12 to 18 months after CABG than
patients who underwent open harvesting (46.7% vs 38.0%, P  .001).
Endoscopic harvesting was also associated with higher rates of death, myo-
cardial infarction, or repeat revascularization at 3 years (20.2% vs 17.4%; ad-
justed hazard ratio [HR], 1.22; 95% confidence interval [CI], 1.01-1.47; P 
.04), death or myocardial infarction (9.3% vs 7.6%; adjustedHR, 1.38; 95%CI,
1.07-1.77; P  .01), and death (7.4% vs 5.8%; adjusted HR, 1.52; 95% CI,
1.13-2.04; P .005).
Comment: Endoscopic vein harvesting is widely believed to be associ-
ated with reduced wound-related complications, improved patient satisfac-
tion, and decreased length of hospital stay. These beliefs are based on very
short-term data. In 13 studies of endoscopic vein harvesting for coronary
surgery analyzed in a meta-analysis of 2005 (Innovations: Technology and
Techniques in Cardiothoracic and Vascular Surgery 2005;1:61-74), all but
one of the 13 studies included in the meta-analysis had data limited to only
4 to 6 weeks of follow-up. Therefore, although the current study is not
randomized for type of vein harvest, it represents a major addition to the
vascular literature. Clearly, patients prefer endoscopic harvest for CABG, the
study was not primarily designed to compare endoscopic and open vein
harvest, and better tools are now available for endoscopic harvest. Despite
this, the study should make surgeons question the continued use of endo-
vascular harvesting of saphenous veins for CABG. The data should also give
serious pause to those using endoscopic techniques to harvest the saphenous
vein for infrainguinal surgery.
Inflammation Impairs Reverse Cholesterol Transport In Vivo
McGillicuddy FC, de la Llera Moya M, Hinkle CC. Circulation 2009;19:
1135-45.
Conclusions: Attenuation of reverse cholesterol transport (RCT) and
high-density lipoprotein (HDL) efflux may contribute to atherosclerosis in
chronic inflammatory states such as obesity, type 2 diabetes, or themetabolic
syndrome, and this is independent of HDL cholesterol levels.
Summary: RCT is a process by which cholesterol in cells such as
lipid-laden foam cells is effluxed onto circulating HDL and transported back
to the liver with secretion into the bile and subsequently into feces (Circu-
lation 2006;113:2548-55). The key atheroprotective effect of HDL is
considered to be promotion of RCT. RCT is a complex process comprising
several regulated steps, among them are macrophage cholesterol efflux,
HDL cholesterol acceptor function, liver uptake of cholesterol, and choles-
terol elimination into bile and feces. Chronic atherosclerosis is marked by
inflammation and inflammation is thought to retard RCT. This impairment
of RCT by inflammation offers a potential mechanism for the association of
inflammation and atherosclerosis. The authors used a rodent macrophage-to-
feces RCT model in this study. This model tracks 3H-cholesterol from
intraperitoneally injected JE744 macrophages onto HDL in plasma and
subsequent uptake by the liver with clearance into bile or feces. They also
performed proof of concept endotoxemia studies in humans. Endotoxemia
reduced 3H-cholesteol movement from macrophage to plasma and 3H-
cholesterol associated with HDL fractions. At 48-hours, endotoxemia re-
duces bile and fecal counts of 3H-cholesterol. This was consistent with
down-regulation of hepatic expression of ABCG8 and ABCG5 as well as
ABCB11 biliary transporters. Low-dose lipopolysaccharide also reduced bile
and fecal counts of 3H-cholesterol and expression of biliary transporters.
The lipopolysaccharide effect occurred in the absence of effects on plasma or
liver counts of 3H-cholesterol.
Inflammation was then produced in healthy human volunteers by
intravenous injection of U.S. standard reference endotoxin at a dose previ-
ously shown to produce a significant inflammatory response. Blood samples
were collected, and ex vivo macrophage cholesterol efflux to acute-phase
HDL was attenuated by the endotoxemia-induced inflammatory response.
Comment: The authors have shown for the first time that acute
inflammation impairs multiple steps of RCT in vivo. They used translational
proof of concept studies to demonstrate that experimental inflammation in
humans can retard cholesterol efflux from human macrophages and reduce
HDL cholesterol acceptor function in vivo by down-regulating specific
biliary transporters of cholesterol. This is elegant translational research that
supports the concept that chronic inflammatory states such as obesity, type 2
diabetes, and the metabolic syndrome may contribute to atherosclerosis by
impairment of RCT.
The Influence of Body Mass Index on Mortality and Bleeding Among
Patients with or at High-Risk of Atherothrombotic Disease
Mak K-H, Bhatt DL, Shao M, et al. Eur Heart J 2009;30:857-65.
Conclusions: In patients with or at risk for atherothrombotic disease,
adverse cardiovascular events and bleeding complications occur more fre-
quently in those with a low body mass index (BMI).
